-
Mashup Score: 4Online Event - 7 month(s) ago
In this live webinar, one of the pioneers of human genome editing—Dr. Fyodor Urnov—will lay out the urgent challenge facing the clinical genome editing community in terms of expanding the public health impact of CRISPR-Cas. A formidable financial, logistical, and regulatory hurdle in all genetic therapies is attaining scalable clinic-grade manufacture of the experimental therapeutic. The current costs, timelines, and requirements in that space make the vast majority of genetic disease intractable in a
Source: www.workcast.comCategories: Future of Medicine, Latest HeadlinesTweet
-
Mashup Score: 0Online Event - 7 month(s) ago
In this live webinar, one of the pioneers of human genome editing—Dr. Fyodor Urnov—will lay out the urgent challenge facing the clinical genome editing community in terms of expanding the public health impact of CRISPR-Cas. A formidable financial, logistical, and regulatory hurdle in all genetic therapies is attaining scalable clinic-grade manufacture of the experimental therapeutic. The current costs, timelines, and requirements in that space make the vast majority of genetic disease intractable in a
Source: www.workcast.comCategories: Future of Medicine, Latest HeadlinesTweet
-
Mashup Score: 0Online Event - 7 month(s) ago
In this live webinar, one of the pioneers of human genome editing—Dr. Fyodor Urnov—will lay out the urgent challenge facing the clinical genome editing community in terms of expanding the public health impact of CRISPR-Cas. A formidable financial, logistical, and regulatory hurdle in all genetic therapies is attaining scalable clinic-grade manufacture of the experimental therapeutic. The current costs, timelines, and requirements in that space make the vast majority of genetic disease intractable in a
Source: www.workcast.comCategories: Future of Medicine, Latest HeadlinesTweet
-
Mashup Score: 9Avian Flu Target in Chickens Disguised by CRISPR - 7 month(s) ago
In a first, CRISPR has generated chickens partially resistant to infection by influenza virus A through genome editing of the ANP32 gene family.
Source: www.genengnews.comCategories: Future of Medicine, Latest HeadlinesTweet
-
Mashup Score: 3Online Event - 7 month(s) ago
In this live webinar, one of the pioneers of human genome editing—Dr. Fyodor Urnov—will lay out the urgent challenge facing the clinical genome editing community in terms of expanding the public health impact of CRISPR-Cas. A formidable financial, logistical, and regulatory hurdle in all genetic therapies is attaining scalable clinic-grade manufacture of the experimental therapeutic. The current costs, timelines, and requirements in that space make the vast majority of genetic disease intractable in a
Source: www.workcast.comCategories: Future of Medicine, Latest HeadlinesTweet
-
Mashup Score: 2Online Event - 7 month(s) ago
In this live webinar, one of the pioneers of human genome editing—Dr. Fyodor Urnov—will lay out the urgent challenge facing the clinical genome editing community in terms of expanding the public health impact of CRISPR-Cas. A formidable financial, logistical, and regulatory hurdle in all genetic therapies is attaining scalable clinic-grade manufacture of the experimental therapeutic. The current costs, timelines, and requirements in that space make the vast majority of genetic disease intractable in a
Source: www.workcast.comCategories: Future of Medicine, Latest HeadlinesTweet
-
Mashup Score: 0Online Event - 7 month(s) ago
In this live webinar, one of the pioneers of human genome editing—Dr. Fyodor Urnov—will lay out the urgent challenge facing the clinical genome editing community in terms of expanding the public health impact of CRISPR-Cas. A formidable financial, logistical, and regulatory hurdle in all genetic therapies is attaining scalable clinic-grade manufacture of the experimental therapeutic. The current costs, timelines, and requirements in that space make the vast majority of genetic disease intractable in a
Source: www.workcast.comCategories: Future of Medicine, Latest HeadlinesTweet
-
Mashup Score: 3
As a part of the NIST Genome Editing Consortium, BioSkryb will help define standards in genome editing research and commercialization.
Source: www.genengnews.comCategories: Future of Medicine, Latest HeadlinesTweet
-
Mashup Score: 2Home - Cracking the Code: The Dawn of Nucleic Acid Medicines - 9 month(s) ago
The conference will discuss the development of nucleic acid medicines — both the recent clinical successes, and current and upcoming challenges. By bringing together academics in basic and translational research and their peers in thriving biotechnology companies and promising start-ups, the conference aims to foster dialog and to spearhead collaborations. The first day (October 17, 2023) will…
Source: www.cvent.comCategories: Future of Medicine, Latest HeadlinesTweet
-
Mashup Score: 2CRISPR'd Rice Resistant to Major Fungal Pest - 10 month(s) ago
Genome editing creates disease resistant rice; finding could increase yield of the crop that feeds half the world.
Categories: Future of Medicine, Latest HeadlinesTweet
TODAY at 1 PM ET, @UrnovFyodor will lay out the urgent challenge facing the clinical #genomeediting community regarding expanding the public health impact of CRISPR-Cas. Don't worry if you can't make it live--it will be available on demand. Register: https://t.co/9Gk2wFxlaP https://t.co/Bqn2HySQOh